Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.

Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL.

Prostate. 2013 Aug;73(11):1214-22. doi: 10.1002/pros.22671. Epub 2013 Apr 30.

2.

Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA.

Eur Urol. 2014 Mar;65(3):635-41. doi: 10.1016/j.eururo.2013.01.007. Epub 2013 Jan 14.

PMID:
23351721
3.

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P.

Eur Urol. 2014 Jun;65(6):1069-75. doi: 10.1016/j.eururo.2013.12.058. Epub 2014 Jan 4.

4.

Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.

Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG.

BJU Int. 2013 May;111(6):954-62. doi: 10.1111/j.1464-410X.2012.11639.x. Epub 2013 Mar 6.

5.

CYP17 polymorphisms and prostate cancer outcomes.

Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL.

Prostate. 2010 Jul 1;70(10):1094-101. doi: 10.1002/pros.21143.

6.

Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010.

Jespersen CG, Nørgaard M, Friis S, Skriver C, Borre M.

Cancer Epidemiol. 2014 Feb;38(1):42-7. doi: 10.1016/j.canep.2013.10.010. Epub 2013 Nov 22.

PMID:
24275259
7.

Statin use and prostate cancer risk in a large population-based setting.

Boudreau DM, Yu O, Buist DS, Miglioretti DL.

Cancer Causes Control. 2008 Sep;19(7):767-74. doi: 10.1007/s10552-008-9139-4. Epub 2008 Mar 6.

8.

Statin drugs and risk of advanced prostate cancer.

Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E.

J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25.

PMID:
17179483
9.

Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.

Lehman DM, Lorenzo C, Hernandez J, Wang CP.

Diabetes Care. 2012 May;35(5):1002-7. doi: 10.2337/dc11-1829. Epub 2012 Mar 28.

10.

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Cancer. 2010 Jul 15;116(14):3389-98. doi: 10.1002/cncr.25308.

11.

Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.

Song C, Park S, Park J, Shim M, Kim A, Jeong IG, Hong JH, Kim CS, Ahn H.

Prostate. 2015 Feb;75(2):211-7. doi: 10.1002/pros.22907. Epub 2014 Oct 18.

PMID:
25327522
12.

Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer.

Ishak-Howard MB, Okoth LA, Cooney KA.

Urology. 2014 Jun;83(6):1356-61. doi: 10.1016/j.urology.2014.02.015. Epub 2014 Apr 16.

13.

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL.

J Clin Oncol. 2010 Jun 1;28(16):2653-9. doi: 10.1200/JCO.2009.27.3003. Epub 2010 Apr 26.

PMID:
20421534
14.

Statin use after colorectal cancer diagnosis and survival: a population-based cohort study.

Cardwell CR, Hicks BM, Hughes C, Murray LJ.

J Clin Oncol. 2014 Oct 1;32(28):3177-83. doi: 10.1200/JCO.2013.54.4569. Epub 2014 Aug 4.

PMID:
25092779
15.

Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis.

Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL.

Cancer Epidemiol. 2013 Oct;37(5):666-70. doi: 10.1016/j.canep.2013.07.005. Epub 2013 Aug 20.

16.

Statin use and risk of disease recurrence and death after radical prostatectomy.

Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ.

Prostate. 2016 Apr;76(5):469-78. doi: 10.1002/pros.23138. Epub 2015 Dec 22.

PMID:
26689439
17.

Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL.

J Natl Cancer Inst. 2011 Oct 5;103(19):1461-8. doi: 10.1093/jnci/djr291. Epub 2011 Aug 2.

18.

Association Between Statin Use After Diagnosis of Esophageal Cancer and Survival: A Population-Based Cohort Study.

Alexandre L, Clark AB, Bhutta HY, Chan SS, Lewis MP, Hart AR.

Gastroenterology. 2016 Apr;150(4):854-65.e1; quiz e16-7. doi: 10.1053/j.gastro.2015.12.039. Epub 2016 Jan 9.

PMID:
26775632
19.

Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.

PMID:
26181182
20.

Statin use after diagnosis of breast cancer and survival: a population-based cohort study.

Cardwell CR, Hicks BM, Hughes C, Murray LJ.

Epidemiology. 2015 Jan;26(1):68-78. doi: 10.1097/EDE.0000000000000189.

PMID:
25304447

Supplemental Content

Support Center